Everolimus-Eluting Platinum Chromium Coronary Stent System
SYNERGY™ BP Stent Clinical Overview
The SYNERGY Bioabsorbable Polymer (BP) Stent Platform has been studied in over 35,000 patients across various patient and lesion complexities.
Heal With Confidence: Leading in Complex Patients
SYNTAX II Trial
The SYNTAX II Trial utilizing the SYNERGY BP Stent, physiological assessment, IVUS guidance, and contemporary state-of-the art PCI techniques demonstrated CABG-like outcomes in patients with three-vessel disease at 3-years.*†¹
Low rates of revascularization, peri-procedural MI, and acute ST suggests that contemporary technologies might help in reducing procedural related complications.
Consistently Low ST Rates
SYNERGY BP Stent ranked #1 for the lowest relative risk of def/prob ST At 1-year. §²
Leading On Studying Short DAPT
Studies the safety of discontinuing DAPT at 3-months in high bleeding risk patients using the SYNERGY BP Stent.
The SYNERGY BP Stent continued to show superior results versus REBEL BMS with short BMS-like DAPT regimen at 2-years.
Discover best-in-class strength, unmatched overexpansion, maximum visibility and uniform lesion scaffolding.